Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Conclusion: Elderly patients with NVAF in the U.S. who continued with apixaban treatment had a lower risk of MB-related hospitalization and lower MB- and stroke/SE-related medical costs compared to patients who switched to another OAC.
PMID: 31120309 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Atrial Fibrillation | Bleeding | Databases & Libraries | Healthcare Costs | Research | Stroke | Study